Results 81 to 90 of about 63,889 (276)
Gut and LiverBackground/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song +7 more
doaj +1 more source
, 2014 Introduction . Erythema dyschromicum perstans (EDP) or ashy dermatosis is a rare, benign acquired disease characterized by macular hyperpigmentations.
Michał Sobjanek +4 more
core +1 more source
Infliximab for the treatment of plaque psoriasis
, 2008 Jennifer S Gall, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Infliximab is a monoclonal antibody that targets tumor necrosis factor-α (TNF& ...
Jennifer S Gall, Robert E Kalb
core
, 1996 Infliximab is a TNF-alpha inhibitor in the form of a chimeric monoclonal antibody. It received FDA approval in 2006 for the treatment of adult patients with severe chronic plaque psoriasis who developed side effects with conventional therapies or in whom
Sagduyu, Ilgen Ertam, Oran, İsmail
core +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Gut and Liver, 2015 Background/AimsIn patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission.
doaj +1 more source
Infliximab in the treatment of plaque type psoriasis
, 2009 Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by ...
Andrea Saggini +3 more
core
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry [PDF]
, 2018 Bjorn Gudbjornsson,1,2 Arni Jon Geirsson,3,4 Niels Steen Krogh5 1Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland; 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 3Department of Rheumatology, University Hospital,
Geirsson AJ +5 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
, 2019 Farhad Salehzadeh,1 Yusef Mohammadikebar,2 Afsaneh Enteshary,2 Omid Ghanbarpour,1 Mehrdad Mirzarahimi11Department of Pediatric, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran; 2Department of Internal ...
Salehzadeh F +4 more
core